Erasca (ERAS) Competitors $2.87 +0.15 (+5.51%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ERAS vs. RLAY, NUVB, VERV, BCYC, LYEL, ZLAB, KYMR, RYTM, MLTX, and DYNShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Relay Therapeutics (RLAY), Nuvation Bio (NUVB), Verve Therapeutics (VERV), Bicycle Therapeutics (BCYC), Lyell Immunopharma (LYEL), Zai Lab (ZLAB), Kymera Therapeutics (KYMR), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Relay Therapeutics Nuvation Bio Verve Therapeutics Bicycle Therapeutics Lyell Immunopharma Zai Lab Kymera Therapeutics Rhythm Pharmaceuticals MoonLake Immunotherapeutics Dyne Therapeutics Erasca (NASDAQ:ERAS) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Do analysts prefer ERAS or RLAY? Erasca presently has a consensus target price of $6.10, suggesting a potential upside of 112.54%. Relay Therapeutics has a consensus target price of $21.11, suggesting a potential upside of 260.87%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Is ERAS or RLAY more profitable? Relay Therapeutics' return on equity of -43.66% beat Erasca's return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -45.38% -37.01% Relay Therapeutics N/A -43.66%-38.38% Do institutionals & insiders hold more shares of ERAS or RLAY? 67.8% of Erasca shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 21.5% of Erasca shares are owned by company insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor ERAS or RLAY? Relay Therapeutics received 32 more outperform votes than Erasca when rated by MarketBeat users. However, 68.75% of users gave Erasca an outperform vote while only 67.50% of users gave Relay Therapeutics an outperform vote. CompanyUnderperformOutperformErascaOutperform Votes2268.75% Underperform Votes1031.25% Relay TherapeuticsOutperform Votes5467.50% Underperform Votes2632.50% Which has preferable earnings & valuation, ERAS or RLAY? Erasca has higher earnings, but lower revenue than Relay Therapeutics. Erasca is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$125.04M-$0.92-3.12Relay Therapeutics$25.55M30.66-$341.97M-$2.52-2.32 Does the media refer more to ERAS or RLAY? In the previous week, Relay Therapeutics had 3 more articles in the media than Erasca. MarketBeat recorded 6 mentions for Relay Therapeutics and 3 mentions for Erasca. Relay Therapeutics' average media sentiment score of 0.06 beat Erasca's score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, ERAS or RLAY? Erasca has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. SummaryRelay Therapeutics beats Erasca on 11 of the 16 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$810.79M$6.74B$5.02B$8.40BDividend YieldN/A7.94%7.52%4.16%P/E Ratio-3.1211.84128.6416.67Price / SalesN/A269.811,718.2576.46Price / CashN/A46.0936.9133.53Price / Book1.375.304.595.18Net Income-$125.04M$150.82M$114.09M$223.67M7 Day Performance8.71%-1.09%110.28%2.59%1 Month Performance12.99%15.18%124.25%8.66%1 Year Performance18.60%36.68%154.82%28.23% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.0255 of 5 stars$2.87+5.5%$6.10+112.5%+18.6%$768.41MN/A-3.12126RLAYRelay Therapeutics3.3298 of 5 stars$5.85+0.2%$21.11+260.9%-22.2%$781.92M$25.55M-2.32304Upcoming EarningsNUVBNuvation Bio3.4959 of 5 stars$2.29-0.4%$6.40+179.5%+69.6%$573.26MN/A-1.0960Upcoming EarningsVERVVerve Therapeutics1.9318 of 5 stars$6.05+2.0%$26.00+329.8%-61.2%$501.82M$11.76M-2.34110BCYCBicycle Therapeutics2.7285 of 5 stars$23.46+3.3%$45.13+92.3%+51.1%$1.11B$26.98M-7.13240Earnings ReportLYELLyell Immunopharma0.4385 of 5 stars$1.27+13.4%$1.00-21.3%-40.7%$286.72M$130,000.00-1.55270Gap DownZLABZai Lab2.8881 of 5 stars$30.89+1.4%$52.50+70.0%+20.1%$3.03B$266.72M-10.092,175Upcoming EarningsKYMRKymera Therapeutics0.9354 of 5 stars$47.07+1.3%$50.93+8.2%+229.9%$3.01B$78.59M-20.12170Earnings ReportAnalyst ForecastAnalyst RevisionGap DownRYTMRhythm Pharmaceuticals3.6096 of 5 stars$52.99+8.1%$60.33+13.9%+96.5%$3.00B$77.43M-12.15140High Trading VolumeMLTXMoonLake Immunotherapeutics1.8971 of 5 stars$46.40-0.8%$80.45+73.4%-9.5%$2.99BN/A-50.992Upcoming EarningsPositive NewsDYNDyne Therapeutics3.3181 of 5 stars$28.78+0.1%$50.60+75.8%+249.7%$2.89BN/A-8.02100Gap Down Related Companies and Tools Related Companies Relay Therapeutics Alternatives Nuvation Bio Alternatives Verve Therapeutics Alternatives Bicycle Therapeutics Alternatives Lyell Immunopharma Alternatives Zai Lab Alternatives Kymera Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Dyne Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ERAS) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ERAS Stock Alerts